UTHR Overview

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia.

Wall Street analysts forecast UTHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UTHR is534.50 USD with a low forecast of 423.00 USD and a high forecast of 645.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

United Therapeutics Corp revenue for the last quarter amounts to 781.50M USD, decreased -1.62

United Therapeutics Corp. EPS for the last quarter amounts to 5.82 USD, decreased -12.22

United Therapeutics Corp (UTHR) has 1400 emplpoyees as of July 08 2026.

Today UTHR has the market capitalization of 23.93B USD.